| __timestamp | Taro Pharmaceutical Industries Ltd. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 179279000 | 17293000 |
| Thursday, January 1, 2015 | 186359000 | 26470000 |
| Friday, January 1, 2016 | 171785000 | 28307000 |
| Sunday, January 1, 2017 | 208136000 | 30354000 |
| Monday, January 1, 2018 | 198405000 | 32160000 |
| Tuesday, January 1, 2019 | 224169000 | 37571000 |
| Wednesday, January 1, 2020 | 245044000 | 39951000 |
| Friday, January 1, 2021 | 252314000 | 50159000 |
| Saturday, January 1, 2022 | 268225000 | 54577000 |
| Sunday, January 1, 2023 | 304629000 | 61940000 |
| Monday, January 1, 2024 | 324203000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. From 2014 to 2023, Taro Pharmaceutical Industries Ltd. consistently outpaced Vericel Corporation in cost of revenue, with Taro's costs peaking at over 320 million in 2023, marking an impressive 81% increase from 2014. In contrast, Vericel's costs grew by 258% over the same period, reaching approximately 62 million in 2023. This stark difference highlights Taro's larger scale of operations. However, Vericel's rapid growth trajectory suggests a strategic expansion. Notably, data for 2024 is incomplete, indicating potential shifts in the coming year. These insights provide a window into the financial strategies of these companies, offering investors a glimpse into their operational efficiencies and market positioning.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Novo Nordisk A/S and Vericel Corporation
Cost of Revenue: Key Insights for Zoetis Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Vericel Corporation
Cost of Revenue Comparison: BeiGene, Ltd. vs Vericel Corporation
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Evotec SE